Shigellainfection continues to have a high disease burden worldwide, especially in young children in developing countries. Here, the latest progress inShigella vaccine research is reviewed—including the identification of new vaccine antigens and technological advances in vaccine design and manufacture—as well as the barriers that impede the development of a successful Shigellavaccine.
- Eileen M. Barry
- Marcela F. Pasetti
- Myron M. Levine